Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
BAPTA-AM is a selective, membrane-permeable and intracellular calcium chelator. In the human leukemia cell lines HL-60 and U937, BAPTA/AM (10 μM) induced internucleosomal DNA cleavage and classic apoptotic morphology. Also, BAPTA/AM increased Ca2+ in intracellular and downregulated c-jun. In bovine chromaffin cells, APTA-AM (50 μM) rapidly and reversibly inhibited Ca2+-activated K+ (I(KCa)) and voltage-gated K+ (I(K)) by 50%. In HEK 293 cells, BAPTA-AM inhibited hERG (Kv11.1), hKv1.3 and hKv1.5 channels with IC50 values of 1.3, 1.45 and 1.23 μM respectively in a concentration dependent way.
ln Vitro |
By chelating intracellular Ca2+, BAPTA-AM upregulates the reduced cardiac sodium current (INa) density and inhibits neuronal Ca2+-activated K+ channel currents[1]. In mouse cortical cultures, lipoxygenase-mediated free radicals cause delayed necrosis, which is induced by the intracellular calcium chelator BAPTA-AM (BAPTA/AM). BAPTA-AM shields neurons from ischemia damage, preventing free radical-mediated toxicity and promoting death in non-neuronal cells while also having a positive effect on neuronal cells. Furthermore, it has been proposed that BAPTA-AM causes an increase in intracellular calcium in I-IL-60 neoplastic cells at a later time rather than an earlier one. Increased release of lactate dehydrogenase (LDH) into the bathing medium after 24 or 48 hours indicates a moderate (45-70%) neuronal damage in mixed cortical cell cultures (DIV 13-16) subjected to 10 μM BAPTA-AM. 48 hours of exposure to 3–10 μM BAPTA–AM causes dose-dependent neuronal damage in cortical cultures[2].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Tang Q, et al. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells. Biochem Pharmacol. 2007 Dec 3;74(11):1596-607.
[2]. Wie MB, et al. BAPTA/AM, an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Nov;25(8):1641-59 |
Molecular Formula |
C34H40N2O18
|
|
---|---|---|
Molecular Weight |
764.68
|
|
CAS # |
126150-97-8
|
|
Related CAS # |
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
O(C([H])([H])C([H])([H])OC1=C([H])C([H])=C([H])C([H])=C1N(C([H])([H])C(=O)OC([H])([H])OC(C([H])([H])[H])=O)C([H])([H])C(=O)OC([H])([H])OC(C([H])([H])[H])=O)C1=C([H])C([H])=C([H])C([H])=C1N(C([H])([H])C(=O)OC([H])([H])OC(C([H])([H])[H])=O)C([H])([H])C(=O)OC([H])([H])OC(C([H])([H])[H])=O
|
|
Chemical Name |
Acetyloxymethyl 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.27 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3077 mL | 6.5387 mL | 13.0774 mL | |
5 mM | 0.2615 mL | 1.3077 mL | 2.6155 mL | |
10 mM | 0.1308 mL | 0.6539 mL | 1.3077 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Calcium chelator BAPTA-AM inhibits ROS production and protects against collapse of mitochondrial membrane potential induced by iron overload. (A) Chondrocytes were treated with 100 µm FAC in the presence or absence of 10 µm of the calcium chelator BAPTA-AM. The quenching of green fluorescence indicates that the intracellular ROS level was reduced in cells treated with BAPTA-AM. Scale bars, 400 µm. (B) Representative fluorescence microscopy photomicrographs of mitochondrial membrane potential following incubation with JC-1. Red fluorescence indicates healthy mitochondria, whereas green fluorescence indicates mitochondrial dysfunction and mitochondrial membrane potential dissipation. Merged images show colocalization of JC-1 aggregates and monomers. Scale bars, 200 µm. (C) Representative graphs of flow cytometric analysis of the altered mitochondrial membrane potential following incubation with JC-1 dye. (D) Bar graphs showing the changes in mitochondrial membrane potential detected by flow cytometry. Scale bars, 200 µm. Data are expressed as the mean ± SD. *P<0.05 vs. Ctrl; #P<0.05 vs. FAC treatment group. FAC, ferric ammonium citrate; BAPTA-AM, BAPTA acetoxymethyl ester; ROS, reactive oxygen species; Ctrl, control group; FAC + BA, FAC + BAPTA-AM group. Int J Mol Med . 2021 Oct;48(4):196. td> |
Calcium chelator BAPTA-AM protects chondrocytes against iron overload-induced mitochondrial damage. (A) Representative fluorescence images of mitochondria and local amplification images of the selected area. Chondrocytes were treated with 100 µm FAC in the presence or absence of 10 µm of the calcium chelator BAPTA-AM and the morphology of the mitochondria was visualized using Mito-Tracker Green staining. Scale bars, 25 µm. (B) Chondrocytes were treated with 100 µm FAC or 10 ng/ml IL-1 β in the presence or absence of 10 µm of the calcium chelator BAPTA-AM. Western blotting was conducted to examine the protein expression levels of MFF, DRP1 and FIS1. (C) Densitometric analysis of MFF, DRP1 and FIS1 protein expression normalized to β-actin. Data are presented as mean ± SD. *P<0.05; ***P<0.001. MFF, mitochondrial fission factor; DRP1, dynamin-related protein 1; FIS1, mitochondrial fission 1 protein; FAC, ferric ammonium citrate; BAPTA-AM, BAPTA acetoxymethyl ester; Ctrl, control group; FAC + BA, FAC + BAPTA-AM group. Int J Mol Med . 2021 Oct;48(4):196. td> |
Calcium chelator BAPTA-AM protects chondrocytes against iron overload-induced apoptosis and lowers MMP expression. (A and B) Chondrocytes were treated with 100 µm FAC in the presence or absence of 10 µm calcium chelator BAPTA-AM for 24 h, and Annexin V-FITC/PI flow cytometric analysis was conducted to detect the apoptotic rate following FAC and BAPTA-AM treatment. Data are presented as mean ± SD. *P<0.05 vs. Ctrl; #P<0.05 vs. FAC treatment group. (C and D) Chondrocytes were treated with 100 µm FAC or 10 ng/ml IL-1 β in the presence or absence of 10 µm calcium chelator BAPTA-AM. Western blotting was conducted to examine the protein expression levels of MMP3 and MMP13. (C) Densitometric analysis of MMP3 and MMP13 protein expression normalized to β-actin. Data are presented as mean ± SD. *P<0.05; **P<0.01; ***P<0.001. FAC, ferric ammonium citrate; BAPTA-AM, BAPTA acetoxymethyl ester; Ctrl, control group; FAC + BA, FAC + BAPTA-AM group. Int J Mol Med . 2021 Oct;48(4):196. td> |